{"version":"1.0","provider_name":"Myanmar News Gazette","provider_url":"https:\/\/myanmarnewsgazette.com","author_name":"admin","author_url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/","title":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"me3fv6OIO8\"><a href=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\">Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/embed\/#?secret=me3fv6OIO8\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting&#8221; &#8212; Myanmar News Gazette\" data-secret=\"me3fv6OIO8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"\u2014 Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation. Combination dose expansion is under way. \u2014 Among the 28 evaluable patients who received the combination regimen, while 85.7% of the patients [\u2026]","thumbnail_url":"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png"}